Richard C. Mohs, Ph.D.

Richard C. Mohs is the Chief Science Officer for the Global Alzheimer's Platform (GAP) Foundation, a patient-centered, non-profit organization devoted to enhancing the speed and quality with which new treatments for Alzheimer's disease are developed. He retired in 2015 from Eli Lilly and Company where he held several leadership positions including Vice President for Neuroscience Early Clinical Development (2012-2015) and Leader of the Global Alzheimer's Drug Development Team (2007-2012). Dr. Mohs received the Ph.D. in psychology from Stanford University and completed postdoctoral training in pharmacology at the Stanford University Medical School. Before joining Eli Lilly in 2002, Dr. Mohs spent 23 years with the Mount Sinai School of Medicine in New York City where he was Professor in the Department of Psychiatry and Associate Chief of Staff for Research at the Bronx Veterans Affairs Medical Center. He is the author or co-author of over 350 scientific papers, including those describing clinical trials that led to the approval, in the U.S. and other countries, of cholinergic drug treatments for Alzheimer's disease. In addition to his work for the GAP Foundation, Dr. Mohs serves as a consultant to academic institutions, foundations and biopharmaceutical companies including Agenebio, a Baltimore-based company developing an SV2A antagonist for treatment of mild cognitive impairment. He also serves as a member of the Board of Governors for the Alzheimer's Drug Discovery Foundation, a member of the Board of Directors for CogState, Ltd, based in Melbourne, Australia, and as Senior Associate Editor for Alzheimer's and Dementia, the journal of the Alzheimer's Association.